연구동향 분석
박사

Clinicopathologic significance of CEP17 copy number gain in breast cancer

이경열 2019년

논문상세정보
인용/피인용
' Clinicopathologic significance of CEP17 copy number gain in breast cancer' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의료과학 약
  • CEP17 copy number gain, HER2, breast cancer, chromosomal instability, next generation sequencing
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
3,950 0

0.0%

' Clinicopathologic significance of CEP17 copy number gain in breast cancer' 의 참고문헌

  • Zhang W, Yu Y. The important molecular markers on chromosome 17 and their clinical impact in breast cancer. International journal of molecular sciences. 2011;12(9):5672-83.
  • Zedan W, Mourad MI, El-Aziz SM, Salamaa NM, Shalaby AA. Cytogenetic significance of chromosome 17 aberrations and P53 gene mutations as prognostic markers in oral squamous cell carcinoma. Diagnostic pathology. 2015;10:2.
  • Zaczek A, Markiewicz A, Supernat A, Bednarz-Knoll N, Brandt B, Seroczynska B, et al. Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer. Pathology oncology research : POR. 2012;18(4):885-94.
  • Yeh IT, Martin MA, Robetorye RS, Bolla AR, McCaskill C, Shah RK, et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2009;22(9):1169-75.
  • Xu H, Zhu X, Xu Z, Hu Y, Bo S, Xing T, et al. Non-invasive Analysis of Genomic Copy Number Variation in Patients with Hepatocellular Carcinoma by Next Generation DNA Sequencing. J Cancer. 2015;6(3):247-53.
  • Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013.
  • Vincent-Salomon A, Benhamo V, Gravier E, Rigaill G, Gruel N, Robin S, et al. Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas. PLoS One. 2013;8(10):e76496.
  • Vargas-Rondon N, Villegas VE, Rondon-Lagos M. The Role of Chromosomal Instability in Cancer and Therapeutic Responses. Cancers (Basel). 2017;10(1).
  • Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens MR, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(30):4869-74.
  • Tibau A, Lopez-Vilaro L, Perez-Olabarria M, Vazquez T, Pons C, Gich I, et al. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer. Neoplasia. 2014;16(10):861-7.
  • Thompson SL, Bakhoum SF, Compton DA. Mechanisms of chromosomal instability. Curr Biol. 2010;20(6):R285-95.
  • Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, et al. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS One. 2011;6(8):e23543.
  • Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, et al. Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A. 2009;106(21):8671-6.
  • Spears M, Yousif F, Lyttle N, Boutros PC, Munro AF, Twelves C, et al. A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials. Oncotarget. 2015;6(31):31693-701.
  • Spears M, Lyttle N, D'Costa A, Chen BE, Yao CQ, Boutros PC, et al. A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial. Oncotarget. 2016;7(31):49099-106.
  • Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(19):10869-74.
  • Smid M, Hoes M, Sieuwerts AM, Sleijfer S, Zhang Y, Wang Y, et al. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Res Treat. 2011;128(1):23- 30.
  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82.
  • Popescu NC, King CR, Kraus MH. Localization of the human erbB- 2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics. 1989;4(3):362-6.
  • Plantaz D, Mohapatra G, Matthay KK, Pellarin M, Seeger RC, Feuerstein BG. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. The American journal of pathology. 1997;150(1):81-9.
  • Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(28):4307-15.
  • Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer research. 1991;51(2):556-67.
  • Orsaria M, Khelifa S, Buza N, Kamath A, Hui P. Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification. Journal of clinical pathology. 2013;66(12):1070-5.
  • Nielsen KV, Ejlertsen B, Moller S, Jensen MB, Balslev E, Muller S, et al. Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status. Molecular oncology. 2012;6(1):88-97.
  • Munro AF, Twelves C, Thomas JS, Cameron DA, Bartlett JM. Chromosome instability and benefit from adjuvant anthracyclines in breast cancer. Br J Cancer. 2012;107(1):71-4.
  • Moelans CB, de Weger RA, van Diest PJ. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast cancer research and treatment. 2010;120(1):1-7.
  • Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak MA. Can chromosomal instability initiate tumorigenesis? Semin Cancer Biol. 2005;15(1):43-9.
  • McClelland SE. Role of chromosomal instability in cancer progression. Endocr Relat Cancer. 2017;24(9):T23-T31.
  • Marchio C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. The Journal of pathology. 2009;219(1):16-24.
  • Lim TH, Lim AS, Thike AA, Tien SL, Tan PH. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer. Archives of pathology & laboratory medicine. 2016;140(2):140-7.
  • Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR. Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol. 2010;4(3):255-66.
  • Kruger S, Mess F, Bohle A, Feller AC. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. International journal of oncology. 2003;23(1):41-8.
  • Krishnamurti U, Hammers JL, Atem FD, Storto PD, Silverman JF. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2009;22(8):1044-8.
  • Kittaneh M, Montero AJ, Gluck S. Molecular profiling for breast cancer: a comprehensive review. Biomarkers in cancer. 2013;5:61-70.
  • Kim A, Shin HC, Bae YK, Kim MK, Kang SH, Lee SJ, et al. Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status. J Breast Cancer. 2012;15(1):24-33.
  • Ji H, Xuan Q, Nanding A, Zhang H, Zhang Q. The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas. PLoS One. 2015;10(7):e0132824.
  • Jang MH, Kim EJ, Kim HJ, Chung YR, Park SY. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number. Breast cancer research and treatment. 2015;153(1):67-77.
  • Hanna WM, Ruschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol. 2014;27(1):4-18.
  • Gunn S, Yeh IT, Lytvak I, Tirtorahardjo B, Dzidic N, Zadeh S, et al. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity. BMC cancer. 2010;10:396.
  • Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR. Defining 'chromosomal instability'. Trends Genet. 2008;24(2):64-9.
  • Fountzilas G, Dafni U, Bobos M, Kotoula V, Batistatou A, Xanthakis I, et al. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. BMC cancer. 2013;13:163.
  • Endesfelder D, McGranahan N, Birkbak NJ, Szallasi Z, Kschischo M, Graham TA, et al. A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables. Oncotarget. 2011;2(7):529-37.
  • Downs-Kelly E, Yoder BJ, Stoler M, Tubbs RR, Skacel M, Grogan T, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. The American journal of surgical pathology. 2005;29(9):1221-7.
  • Downey L, Livingston RB, Koehler M, Arbushites M, Williams L, Santiago A, et al. Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010;16(4):1281-8.
  • Creighton CJ. The molecular profile of luminal B breast cancer. Biologics : targets & therapy. 2012;6:289-97.
  • Chan KC, Jiang P, Chan CW, Sun K, Wong J, Hui EP, et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci U S A. 2013;110(47):18761-8.
  • Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006;38(9):1043-8.
  • Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
  • Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). The Lancet Oncology. 2010;11(3):266-74.
  • Bakhoum SF, Compton DA. Chromosomal instability and cancer: a complex relationship with therapeutic potential. J Clin Invest. 2012;122(4):1138-43.